The purpose of this study is to test whether giving high doses of carfilzomib along with the
other drugs (lenalidomide and dexamethasone) is safe and which dose is best tolerated by
patients. In addition, the study is designed to test the amount of remaining myeloma cells in
the body after treatment with higher carfilzomib doses which is known as minimal residual
disease (MRD).